Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies

Lecouvet, Frédéric; Geukens, D; Stainier, A.; Jamar, François; Jamart, Jacques; d’Othée, Bertrand Janne; Therasse, Patrick; Berg, Bruno; Tombal, Bertrand

doi:10.1200/jco.2006.09.2940

Cited by 201 publications

(97 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone marrow MRI has been shown to be more sensitive and specific than bone scanning for the detection of bone metastases and to reveal them earlier (74). In a study of 66 patients with high-risk prostate cancer, the sensitivity and specificity of onestep MRI of the axial skeleton (100% and 88%, respectively) were markedly higher than those of bone scanning (46% and 32%, respectively) for detecting bone metastases and changed treatment planning in 22% of patients (75). More research is needed to determine the diagnostic value and cost-effectiveness of one-step MRI in the assessment of bone metastases.…”

Section: Mri In the Pretreatment Detection Of Metastasesmentioning

confidence: 99%

MRI of the prostate: Clinical relevance and emerging applications

Mazaheri

Shukla–Dave

Muellner

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

MRI of the prostate can aid in many aspects of prostate cancer management, from initial detection to treatment planning and follow-up. This review describes the current strengths and limitations of conventional anatomic and molecular MR imaging techniques (including MR spectroscopic imaging and dynamic contrast-enhanced imaging) for aiding prostate cancer management. It also describes promising emerging approaches for acquiring, analyzing, and applying MR imaging data, and the major research and educational efforts that will be required to realize the potential of prostate MR imaging in routine clinical practice.

show abstract

Section: Mri In the Pretreatment Detection Of Metastasesmentioning

confidence: 99%

MRI of the prostate: Clinical relevance and emerging applications

Mazaheri

Shukla–Dave

Muellner

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…A study of 66 patients with high-risk prostate cancer has shown no cases of isolated peripheral metastases (Lecouvet et al, 2007). With newer scanners, coverage of the whole skeleton with MRI by use of whole-body coil arrays or moving table arrangements is possible but it is time consuming, and the difficulty with MR interpretation of certain areas, such as ribs, does not make such intensive imaging worthwhile.…”

Section: Mri For Assessment Of Bone Metastasesmentioning

confidence: 99%

“…Magnetic resonance has been shown to detect bone metastases in 37.5% of patients with negative or inconclusive bone scan and plain films, and one prospective study indicates sensitivities and specificities of 100 and 88% for MRI and 46 and 32% for bone scintigraphy (Lecouvet et al, 2007). The discrepancy between these modalities arises because even with extensive marrow involvement by metastases, the amount of bony matrix destroyed is small (Taoka et al, 2001).…”

Section: Mri For Assessment Of Bone Metastasesmentioning

confidence: 99%

Imaging metastatic bone disease from carcinoma of the prostate

2009

View full text Add to dashboard Cite

Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment response, particularly because of a 'flare' phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment, and newer techniques allow quantitation. In addition to 18 F-fluorodeoxyglucose ( 18 FDG), newer PET isotopes are also showing promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic bony metastases, and links them to the underlying pathological changes within bone lesions. British Journal of Cancer (2009) Prostate cancer is the second most common cancer in men, accounting for 1 in 9 of all new cancers, and with more than 670 000 new diagnoses annually worldwide. The metastatic spread is primarily in the skeleton (supporting the 'seed-and-soil' hypothesis described by Paget in 1889) in which lesions are often located in vertebra and ribs because of dissemination through Batson's venous plexus. The spread in bone also follows the distribution of adult red bone marrow, that is, skull, thorax, pelvis, spine, proximal long bones (Imbriaco et al, 1998;Scher, 2003), subsequently progressing to involve adjacent cortical bone. Preclinical models confirm that skeletal sites rich in cellular marrow with active turnover show increased cancer localisation (Schneider et al, 2005). Although predominantly osteoblastic, osteoclast activation also has an important role in the growth of sclerotic metastases in the bone. In a study of 68 men with prostatic bone metastases who underwent surgery for stabilisation of pathological fracture or impending fracture, most metastases were osteoblastic, but 29.1% had metastases that were osteolytic or mixed (Cheville et al,

show abstract

“…Bone scintigraphy predicts the risk of spinal cord compression, a major cause of morbidity in CRPC [36]. However, scintigraphy may lack sensitivity compared with magnetic resonance imaging (MRI) for early detection of spinal metastases [37].…”

Section: Highlight Clinical Benefitmentioning

confidence: 99%

Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature

Armstrong

Febbo

2009

The Oncologist

View full text Add to dashboard Cite

Recurrent prostate cancer has a complex molecular etiology and a prolonged disease course. Although initially responsive to androgen ablation, many men eventually become castration resistant, develop skeletal metastases, and are palliatively treated with docetaxel-based chemotherapy, radiation therapy, bisphosphonates, and best supportive care. Given the modest success rates of the current standard of care, clinical trial enrollment is encouraged. Castration-resistant prostate cancer (CRPC) is a heterogeneous disease, both in clinical manifestations and outcomes, requiring an individualized approach to both patient care and trial design. Herein, we review surrogate markers of disease progression and treatment efficacy in advanced prostate cancer in light of recently published guidelines that have redefined eligibility, response criteria, and suitable endpoints in prostate cancer drug development. The guidelines have refined outcome measures to potentially better capture clinical benefit and the ability of novel targeted molecular and biologic agents to impact favorably on this disease. We consider prostatespecific antigen changes, circulating tumor cells, bone scan alterations, markers of bone metabolism (urinary N-telopeptide and bone-specific alkaline phosphatase), pain improvements, and progression-free survival. To illustrate the role and challenges of these potential biomarkers and endpoints in drug development, we discuss a class of novel molecularly targeted agents, the src kinase inhibitors. Given that there are currently no validated surrogate markers of overall survival for assessing early clinical benefit from systemic therapy in metastatic CRPC, incorporation of relevant biomarkers into all phases of clinical development is essential to accelerate drug development in this field. The Oncologist

show abstract

Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients With High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies

Abstract: MRIas is more sensitive than the current SW of radiographically identified bone metastases in high-risk PCa patients, which impacts the clinical management of a significant proportion of patients.

Cited by 201 publications

References 44 publications

MRI of the prostate: Clinical relevance and emerging applications

MRI of the prostate: Clinical relevance and emerging applications

Imaging metastatic bone disease from carcinoma of the prostate

Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature

Contact Info

Product

Resources

About